| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.39 | 3e-15 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.27 | 3e-14 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-14 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.24 | 6e-13 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-11 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-10 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.34 | 6e-10 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-09 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-09 |